Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GABRP | O00591 | 2/20 | 0.51 |
| ▸ | GABRD | O14764 | 2/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.51 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.51 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.51 |
| ▸ | GABRE | P78334 | 2/20 | 0.51 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.51 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.51 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.51 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22533152 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL29422641 | 0.98 | ALDH1A1 (0.50) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30800091 | 0.84 | ALDH1A1 (0.54) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30065796 | 0.81 | KDM4E (0.62) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL163424 | 0.81 | ALDH1A1 (0.51) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL131790 | 0.81 | ALDH1A1 (0.51) | ALDH1A1LCKARMAPK1KDM4E | |
| SCHEMBL70350 | 0.81 | KDM4E (0.62) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL27656693 | 0.81 | ALDH1A1 (0.38) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1180030 | 0.81 | FTO (0.52) | ALDH1A1GABRPGABRDGABRA1GABRB1 | |
| SCHEMBL5778009 | 0.80 | CA12 (0.51) | ALDH1A1GABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115991672-A | Preparation method of 4-hydroxypyridine-2-methyl formate | 苏州美诺医药科技有限公司 | 2023-04-21 | — | — | CN | claimed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| US-12522583-B2 | Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4079734-B1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI SIMR BIOTECHNOLOGY CO LTD (CN) | 2025-09-17 | — | — | EP | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| EP-4461355-A2 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-2432771-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| WO-2010135360-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20070054224-A1 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. | 2007-03-08 | — | — | US | disclosed |
| US-7183044-B2 | Silver halide color photographic light-sensitive material | FUJI PHOTO FILM CO., LTD. (JP) | 2007-02-27 | — | — | US | disclosed |
| US-6765009-B2 | N-(5-TERT-BUTYL-3-(3-(4-((2-DIMETHYLAMINOMETHYL-PYRIDIN-4-YL) -PIPERAZIN-1-YL-METHYL) NAPHTHALEN-1-YL)UREIDO)-2-METHOXYPHENYL) METHANESULFONAMIDE FOR EXAMPLE; CYTOKINE INHIBITORS FOR TREATMENT OF INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| EP-1381592-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2004-01-21 | — | — | EP | disclosed |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | BOEHRINGER INTELHEIM PHARMACEUTICALS, INC. | 2003-05-01 | — | — | US | disclosed |
| WO-2002083628-A1 | 1,4-DISUBSTITUTED BENZO-FUSED COMPOUNDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-0276204-A2 | Pyridine gametocides | Monsanto Company (US) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028478-A1 | ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, HRH2 | ALDH1A1 47/4885GABRP 295/4885GABRD 533/4885 |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885GABRP 331/4885GABRD 439/4885 |
| US-20030083333-A1 | 1,4-Disubstituted benzo-fused compounds | RELA, NFKBIA, NQO1 | ALDH1A1 389/4885GABRP 1638/4885GABRD 1052/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885GABRP 331/4885GABRD 439/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | ALDH1A1 632/4885GABRP 18/4885GABRD 20/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | ALDH1A1 3497/4885GABRP 331/4885GABRD 439/4885 |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | ALDH1A1 3087/4885GABRP 137/4885GABRD 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.